Institute of Medicine. Initial national priorities for comparative effectiveness research. Washington, DC: The National Academies Press; 2009.
Google Scholar
Gotzsche PC. Why we need a broad perspective on meta-analysis. It may be crucially important for patients. BMJ. 2000;321(7261):585–6.
Article
CAS
PubMed
PubMed Central
Google Scholar
Jefferson T, Doshi P, Thompson M, Heneghan C. Ensuring safe and effective drugs: who can do what it takes? BMJ. 2011;342:c7258.
Article
PubMed
Google Scholar
Liberati A. Need to realign patient-oriented and commercial and academic research. Lancet. 2011;378(9805):1777–8.
Article
PubMed
Google Scholar
Ioannidis JP. Integration of evidence from multiple meta-analyses: a primer on umbrella reviews, treatment networks and multiple treatments meta-analyses. CMAJ. 2009;181(8):488–93.
Article
PubMed
PubMed Central
Google Scholar
Naci H, Ioannidis JP. How good is “evidence” from clinical studies of drug effects and why might such evidence fail in the prediction of the clinical utility of drugs? Annu Rev Pharmacol Toxicol. 2015;55:169–89.
Article
CAS
PubMed
Google Scholar
Haidich AB, Pilalas D, Contopoulos-Ioannidis DG, Ioannidis JP. Most meta-analyses of drug interventions have narrow scopes and many focus on specific agents. J Clin Epidemiol. 2013;66(4):371–8.
Article
PubMed
Google Scholar
Moher D, Tsertsvadze A, Tricco AC, Eccles M, Grimshaw J, Sampson M, et al. When and how to update systematic reviews. Cochrane Database Syst Rev. 2008;1:MR000023.
PubMed
Google Scholar
Shojania KG, Sampson M, Ansari MT, Ji J, Doucette S, Moher D. How quickly do systematic reviews go out of date? A survival analysis. Ann Intern Med. 2007;147(4):224–33.
Article
PubMed
Google Scholar
Ioannidis JP, Karassa FB. The need to consider the wider agenda in systematic reviews and meta-analyses: breadth, timing, and depth of the evidence. BMJ. 2010;341:c4875.
Article
PubMed
Google Scholar
Global Burden of Disease Cancer Collaboration, Fitzmaurice C, Dicker D, Pain A, Hamavid H, Moradi-Lakeh M, et al. The global burden of cancer 2013. JAMA Oncol. 2015;1(4):505–27.
Article
PubMed Central
Google Scholar
Chan AW. Out of sight but not out of mind: how to search for unpublished clinical trial evidence. BMJ. 2012;344:d8013.
Article
PubMed
Google Scholar
Shea BJ, Grimshaw JM, Wells GA, Boers M, Andersson N, Hamel C, et al. Development of AMSTAR: a measurement tool to assess the methodological quality of systematic reviews. BMC Med Res Methodol. 2007;7:10.
Article
PubMed
PubMed Central
Google Scholar
Shea BJ, Bouter LM, Peterson J, Boers M, Andersson N, Ortiz Z, et al. External validation of a measurement tool to assess systematic reviews (AMSTAR). PLoS One. 2007;2(12):e1350.
Article
PubMed
PubMed Central
Google Scholar
Shea BJ, Hamel C, Wells GA, Bouter LM, Kristjansson E, Grimshaw J, et al. AMSTAR is a reliable and valid measurement tool to assess the methodological quality of systematic reviews. J Clin Epidemiol. 2009;62(10):1013–20.
Article
PubMed
Google Scholar
Chandler J, Churchill R, Higgins J, Lasserson T, Tovey D. Methodological standards for the conduct of new Cochrane Intervention Reviews, Methodological expectations of Cochrane intervention reviews (MECIR). London: Cochrane Editorial Unit; 2013.
Google Scholar
Al-Saleh K, Quinton C, Ellis PM. Role of pemetrexed in advanced non-small-cell lung cancer: meta-analysis of randomized controlled trials, with histology subgroup analysis. Curr Oncol. 2012;19(1):e9–e15.
CAS
PubMed
PubMed Central
Google Scholar
Barlesi F, Jacot W, Astoul P, Pujol JL. Second-line treatment for advanced non-small cell lung cancer: a systematic review. Lung Cancer. 2006;51(2):159–72.
Article
PubMed
Google Scholar
Bonfill X, Serra C, Sacristan M, Nogue M, Losa F, Montesinos J. Second-line chemotherapy for non-small cell lung cancer. Cochrane Database Syst Rev. 2002;2:CD002804.
PubMed
Google Scholar
Cui J, Cai X, Zhu M, Liu T, Zhao N. The efficacy of bevacizumab compared with other targeted drugs for patients with advanced NSCLC: a meta-analysis from 30 randomized controlled clinical trials. PLoS One. 2013;8(4):e62038.
Article
CAS
PubMed
PubMed Central
Google Scholar
Gao G, Ren S, Li A, He Y, Chen X, Li W, et al. A meta-analysis of comparing EGFR-TKI with chemotherapy as the second-line treatment of NSCLC patients with wild-type EGFR. J Clin Oncol. 2013;31(15):suppl 1.
Hawkins N, Scott DA, Woods BS, Thatcher N. No study left behind: a network meta-analysis in non-small-cell lung cancer demonstrating the importance of considering all relevant data. Value Health. 2009;12(6):996–1003.
Article
PubMed
Google Scholar
Jiang J, Huang L, Liang X, Zhou X, Huang R, Chu Z, et al. Gefitinib versus docetaxel in previously treated advanced non-small-cell lung cancer: a meta-analysis of randomized controlled trials. Acta Oncol. 2011;50(4):582–8.
Article
CAS
PubMed
Google Scholar
Jin Y, Sun Y, Shi X, Zhao J, Shi L, Hong W, et al. Meta-analysis to assess the efficacy and toxicity of docetaxel-based doublet compared with docetaxel alone for patients with advanced NSCLC who failed first-line treatment. Clin Ther. 2014;36(12):1980–90.
Article
CAS
PubMed
Google Scholar
Lee JK, Hahn S, Kim DW, Suh KJ, Keam B, Kim TM, et al. Epidermal growth factor receptor tyrosine kinase inhibitors vs conventional chemotherapy in non-small cell lung cancer harboring wild-type epidermal growth factor receptor: a meta-analysis. JAMA. 2014;311(14):1430–7.
Article
PubMed
Google Scholar
Li N, Yang L, Ou W, Zhang L, Zhang SL, Wang SY. Meta-analysis of EGFR tyrosine kinase inhibitors compared with chemotherapy as second-line treatment in pretreated advanced non-small cell lung cancer. PLoS One. 2014;9(7):e102777.
Article
PubMed
PubMed Central
Google Scholar
Li X, Wang H, Lin W, Xu Q. Efficacy of combining targeted therapy with pemetrexed or docetaxel as second-line treatment in patients with advanced non-small-cell lung cancer: a meta-analysis of 14 randomized controlled trials. Curr Med Res Opin. 2014;30(11):2295–304.
Article
CAS
PubMed
Google Scholar
Liang W, Wu X, Hong S, Zhang Y, Kang S, Fang W, et al. Multi-targeted antiangiogenic tyrosine kinase inhibitors in advanced non-small cell lung cancer: meta-analyses of 20 randomized controlled trials and subgroup analyses. PLoS One. 2014;9(10):e109757.
Article
PubMed
PubMed Central
Google Scholar
Perez-Moreno MA, Galvan-Banqueri M, Flores-Moreno S, Villalba-Moreno A, Cotrina-Luque J, Bautista-Paloma FJ. Systematic review of efficacy and safety of pemetrexed in non-small-cell-lung cancer. Int J Clin Pharm. 2014;36(3):476–87.
Article
CAS
PubMed
Google Scholar
Popat S, Mellemgaard A, Fahrbach K, Martin A, Rizzo M, Kaiser R, et al. Nintedanib plus docetaxel as second-line therapy in patients with non-small-cell lung cancer: a network meta-analysis. Future Oncol. 2015;11(3):409–20.
Article
CAS
PubMed
Google Scholar
Qi WX, Shen Z, Lin F, Sun YJ, Min DL, Tang LN, et al. Comparison of the efficacy and safety of EFGR tyrosine kinase inhibitor monotherapy with standard second-line chemotherapy in previously treated advanced non-small-cell lung cancer: a systematic review and meta-analysis. Asian Pac J Cancer Prev. 2012;13(10):5177–82.
Article
PubMed
Google Scholar
Qi WX, Shen Z, Yao Y. Meta-analysis of docetaxel-based doublet versus docetaxel alone as second-line treatment for advanced non-small-cell lung cancer. Cancer Chemother Pharmacol. 2012;69(1):99–106.
Article
CAS
PubMed
Google Scholar
Qi WX, Tang LN, He AN, Shen Z, Yao Y. The role of vandetanib in the second-line treatment for advanced non-small-cell-lung cancer: a meta-analysis of four randomized controlled trials. Lung. 2011;189(6):437–43.
Article
CAS
PubMed
Google Scholar
Qi WX, Tang LN, He AN, Shen Z, Yao Y. Effectiveness and safety of pemetrexed-based doublet versus pemetrexed alone as second-line treatment for advanced non-small-cell lung cancer: a systematic review and meta-analysis. J Cancer Res Clin Oncol. 2012;138(5):745–51.
Article
PubMed
Google Scholar
Qi WX, Wang Q, Jiang YL, Sun YJ, Tang LN, He AN, et al. Overall survival benefits for combining targeted therapy as second-line treatment for advanced non-small-cell-lung cancer: a meta-analysis of published data. PLoS One. 2013;8(2):e55637.
Article
CAS
PubMed
PubMed Central
Google Scholar
Sun CT, Xu X, Sheng W, Wang XW, Wen SL, Han JQ. A meta-analysis of pemetrexed-based doublet compared with pemetrexed alone for the second-line treatment of advanced non-small-cell lung cancer. Bratisl Lek Listy. 2014;115(4):233–7.
CAS
PubMed
Google Scholar
Sun L, Ma JT, Zhang SL, Zou HW, Han CB. Efficacy and safety of chemotherapy or tyrosine kinase inhibitors combined with bevacizumab versus chemotherapy or tyrosine kinase inhibitors alone in the treatment of non-small cell lung cancer: a systematic review and meta-analysis. Med Oncol. 2015;32(2):473.
Article
PubMed
Google Scholar
Tao L, Zhuo W, Yang F, Zhu B. Vandetanib for advanced non-small cell lung cancer: a meta-analysis. Zhongguo Fei Ai Za Zhi. 2012;15(3):172–8.
PubMed
Google Scholar
Tassinari D, Scarpi E, Sartori S, Drudi F, Castellani C, Carloni F, et al. Noninferiority trials in second-line treatments of nonsmall cell lung cancer: a systematic review of literature with meta-analysis of phase III randomized clinical trials. Am J Clin Oncol. 2012;35(6):593–9.
Article
PubMed
Google Scholar
Tassinari D, Scarpi E, Sartori S, Tamburini E, Santelmo C, Tombesi P, et al. Second-line treatments in non-small cell lung cancer. A systematic review of literature and metaanalysis of randomized clinical trials. Chest. 2009;135(6):1596–609.
Article
CAS
PubMed
Google Scholar
Vale CL, Burdett S, Fisher DJ, Navani N, Parmar MK, Copas AJ, et al. Should tyrosine kinase inhibitors be considered for advanced non-small-cell lung cancer patients with wild type EGFR? Two systematic reviews and meta-analyses of randomized trials. Clin Lung Cancer. 2015;16(3):173–82. e174.
Article
CAS
PubMed
PubMed Central
Google Scholar
Wong KM, Victor C, Eng L, Verma S. The use of epidermal growth factor receptor tyrosine kinase inhibitors in treatment of advanced EGFR wild-type non-small cell lung cancer: a meta-analysis study. J Thorac Oncol. 2013;8(suppl 2):S1184.
Xiao BK, Yang JY, Dong JX, Ji ZS, Si HY, Wang WL, et al. Meta-analysis of seven randomized control trials to assess the efficacy and toxicity of combining EGFR-TKI with chemotherapy for patients with advanced NSCLC who failed first-line treatment. Asian Pac J Cancer Prev. 2015;16(7):2915–21.
Article
PubMed
Google Scholar
Yang X, Yang K, Kuang K. The efficacy and safety of EGFR inhibitor monotherapy in non-small cell lung cancer: a systematic review. Curr Oncol Rep. 2014;16(6):390.
Article
PubMed
Google Scholar
Zhao N, Zhang XC, Yan HH, Yang JJ, Wu YL. Efficacy of epidermal growth factor receptor inhibitors versus chemotherapy as second-line treatment in advanced non-small-cell lung cancer with wild-type EGFR: a meta-analysis of randomized controlled clinical trials. Lung Cancer. 2014;85(1):66–73.
Article
PubMed
Google Scholar
Chalmers I, Bracken MB, Djulbegovic B, Garattini S, Grant J, Gulmezoglu AM, et al. How to increase value and reduce waste when research priorities are set. Lancet. 2014;383(9912):156–65.
Article
PubMed
Google Scholar
DeSantis SM, Zhu H. A Bayesian mixed-treatment comparison meta-analysis of treatments for alcohol dependence and implications for planning future trials. Med Decis Making. 2014;34(7):899–910.
Article
PubMed
PubMed Central
Google Scholar
Nikolakopoulou A, Mavridis D, Salanti G. Using conditional power of network meta-analysis (NMA) to inform the design of future clinical trials. Biom J. 2014;56(6):973–90.
Article
PubMed
Google Scholar
Tsafnat G, Dunn A, Glasziou P, Coiera E. The automation of systematic reviews. BMJ. 2013;346:f139.
Article
PubMed
Google Scholar
Tsafnat G, Glasziou P, Choong MK, Dunn A, Galgani F, Coiera E. Systematic review automation technologies. Syst Rev. 2014;3:74.
Article
PubMed
PubMed Central
Google Scholar
Salanti G, Kavvoura FK, Ioannidis JP. Exploring the geometry of treatment networks. Ann Intern Med. 2008;148(7):544–53.
Article
PubMed
Google Scholar
Hutton B, Salanti G, Caldwell DM, Chaimani A, Schmid CH, Cameron C, et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med. 2015;162(11):777–84.
Article
PubMed
Google Scholar
Bafeta A, Trinquart L, Seror R, Ravaud P. Analysis of the systematic reviews process in reports of network meta-analyses: methodological systematic review. BMJ. 2013;347:f3675.
Article
PubMed
PubMed Central
Google Scholar
Caldwell DM, Ades AE, Higgins JP. Simultaneous comparison of multiple treatments: combining direct and indirect evidence. BMJ. 2005;331(7521):897–900.
Article
PubMed
PubMed Central
Google Scholar
Dias S, Welton NJ, Sutton AJ, Ades AE. Evidence synthesis for decision making 1: introduction. Med Decis Making. 2013;33(5):597–606.
Article
PubMed
PubMed Central
Google Scholar
Mills EJ, Kanters S, Thorlund K, Chaimani A, Veroniki AA, Ioannidis JP. The effects of excluding treatments from network meta-analyses: survey. BMJ. 2013;347:f5195.
Article
PubMed
PubMed Central
Google Scholar
Ioannidis JP, Chang CQ, Lam TK, Schully SD, Khoury MJ. The geometric increase in meta-analyses from China in the genomic era. PLoS One. 2013;8(6):e65602.
Article
CAS
PubMed
PubMed Central
Google Scholar
Bastian H, Glasziou P, Chalmers I. Seventy-five trials and eleven systematic reviews a day: how will we ever keep up? PLoS Med. 2010;7(9):e1000326.
Article
PubMed
PubMed Central
Google Scholar
Helfer B, Prosser A, Samara MT, Geddes JR, Cipriani A, Davis JM, et al. Recent meta-analyses neglect previous systematic reviews and meta-analyses about the same topic: a systematic examination. BMC Med. 2015;13(1):82.
Article
PubMed
PubMed Central
Google Scholar
Siontis KC, Hernandez-Boussard T, Ioannidis JP. Overlapping meta-analyses on the same topic: survey of published studies. BMJ. 2013;347:f4501.
Article
PubMed
PubMed Central
Google Scholar
Elliott JH, Turner T, Clavisi O, Thomas J, Higgins JP, Mavergames C, et al. Living systematic reviews: an emerging opportunity to narrow the evidence-practice gap. PLoS Med. 2014;11(2):e1001603.
Article
PubMed
PubMed Central
Google Scholar
Jonnalagadda SR, Goyal P, Huffman MD. Automating data extraction in systematic reviews: a systematic review. Syst Rev. 2015;4:78.
Article
PubMed
PubMed Central
Google Scholar
Marshall IJ, Kuiper J, Wallace BC. Automating risk of bias assessment for clinical trials. IEEE J Biomed Health Inform. 2015;19(4):1406–12.
Article
PubMed
Google Scholar
Badgett RG, Vindhyal M, Stirnaman JT, Gibson CM, Halaby R. A living systematic review of nebulized hypertonic saline for acute bronchiolitis in infants. JAMA Pediatr. 2015;169(8):788–9.
Article
PubMed
Google Scholar
Synnot A, Gruen RL, Menon D, Steyerberg EW, Buki A, Peul W, et al. A new approach to evidence synthesis in traumatic brain injury: living systematic reviews. J Neurotrauma. 2015. Epub ahead of print. doi:10.1089/neu.2015.4124.
Brazinova A, Rehorcikova V, Taylor MS, Buckova V, Majdan M, Psota M, et al. Epidemiology of traumatic brain injury in Europe: a living systematic review. J Neurotrauma. 2015. Epub ahead of print. doi:10.1089/neu.2015.4126
Cnossen MC, Scholten AC, Lingsma H, Synnot A, Tavender E, Gantner D, et al. Adherence to guidelines in adult patients with traumatic brain injury: A living systematic review. J Neurotrauma. 2015. Epub ahead of print. doi:10.1089/neu.2015.4121
Ters P, Badgett RG. A living meta-analysis of colchicine for pericarditis. Ann Pharmacother. 2014;48(10):1398–9.
Article
PubMed
Google Scholar
Handbook for grading the quality of evidence and the strength of recommendations using the GRADE approach. http://gdt.guidelinedevelopment.org/central_prod/_design/client/handbook/handbook.html. Accessed 2 Dec 2015.
Gartlehner G, Flamm M. Is the Cochrane Collaboration prepared for the era of patient-centred outcomes research? Cochrane Database Syst Rev. 2013;3:ED000054.
PubMed
Google Scholar
Naci H, O’Connor AB. Assessing comparative effectiveness of new drugs before approval using prospective network meta-analyses. J Clin Epidemiol. 2013;66(8):812–6.
Article
PubMed
Google Scholar
Puhan MA, Schünemann HJ, Murad MH, Li T, Brignardello-Petersen R, Singh JA, et al. A GRADE Working Group approach for rating the quality of treatment effect estimates from network meta-analysis. BMJ. 2014;349:g5630.
Article
PubMed
Google Scholar
Li T, Rouse B, Shi Q, Dickersin K. Working from all angles. The Inaugural REWARD/EQUATOR Conference: increasing value and reducing waste in biomedical research conference, 28–30 September 2015, Edinburgh, UK.
Haas DM, Caldwell DM, Kirkpatrick P, McIntosh JJ, Welton NJ. Tocolytic therapy for preterm delivery: systematic review and network meta-analysis. BMJ. 2012;345:e6226.
Article
PubMed
PubMed Central
Google Scholar
Smalheiser NR, Lin C, Jia L, Jiang Y, Cohen AM, Yu C, et al. Design and implementation of Metta, a metasearch engine for biomedical literature retrieval intended for systematic reviewers. Health Inf Sci Syst. 2014;2:1.
Article
PubMed
PubMed Central
Google Scholar
OpenTrials. All the Data, on All the Trials, Linked. http://opentrials.net/. Accessed 2 Dec 2015.
Elliott J, Sim I, Thomas J, Owens N, Dooley G, Riis J, et al. #CochraneTech: technology and the future of systematic reviews. Cochrane Database Syst Rev. 2014;9:ED000091.
PubMed
Google Scholar
Embase Screening. http://screening.metaxis.com/EMBASE/login.php. Accessed 2 Dec 2015.
Wallace BC, Trikalinos TA, Lau J, Brodley C, Schmid CH. Semi-automated screening of biomedical citations for systematic reviews. BMC Bioinformatics. 2010;11:55.
Article
PubMed
PubMed Central
Google Scholar
O’Mara-Eves A, Thomas J, McNaught J, Miwa M, Ananiadou S. Using text mining for study identification in systematic reviews: a systematic review of current approaches. Syst Rev. 2015;4:5.
Article
PubMed
PubMed Central
Google Scholar
Miwa M, Thomas J, O'Mara-Eves A, Ananiadou S. Reducing systematic review workload through certainty-based screening. J Biomed Inform. 2014;51:242–53.
Article
PubMed
PubMed Central
Google Scholar
Rathbone J, Hoffmann T, Glasziou P. Faster title and abstract screening? Evaluating Abstrackr, a semi-automated online screening program for systematic reviewers. Syst Rev. 2015;4:80.
Article
PubMed
PubMed Central
Google Scholar
Brown AW, Allison DB. Using crowdsourcing to evaluate published scientific literature: methods and example. PLoS One. 2014;9(7):e100647.
Article
PubMed
PubMed Central
Google Scholar
Cepeda MS, Lobanov V, Berlin JA. From ClinicalTrials.gov trial registry to an analysis-ready database of clinical trial results. Clin Trials. 2013;10(2):347–8.
Article
PubMed
Google Scholar
Tasneem A, Aberle L, Ananth H, Chakraborty S, Chiswell K, McCourt BJ, et al. The database for aggregate analysis of ClinicalTrials.gov (AACT) and subsequent regrouping by clinical specialty. PLoS One. 2012;7(3):e33677.
Article
CAS
PubMed
PubMed Central
Google Scholar
Maruani A, Boutron I, Baron G, Ravaud P. Impact of sending email reminders of the legal requirement for posting results on ClinicalTrials.gov: cohort embedded pragmatic randomized controlled trial. BMJ. 2014;349:g5579.
Article
PubMed
PubMed Central
Google Scholar
openMetaAnalysis. http://openmetaanalysis.github.io/. Accessed 2 Dec 2015.
Rising J, Hsiang S. A tool for distributed meta-analysis. Social Science Research Network; 2014. http://ssrn.com/abstract=2458129. Accessed 2 Dec 2015
Nikolakopoulou A, Mavridis D, Salanti G. Prospective use of network metaanalysis using formal statistical monitoring. 36th Annual Conference of the International Society for Clinical Biostatistics, 23–27 August 2015, Utrecht, The Netherlands.